Journal article
CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination
Vaccine, Vol.35(33), pp.4255-4261
07/24/2017
DOI: 10.1016/j.vaccine.2017.06.013
PMCID: PMC5551405
PMID: 28662951
Abstract
Determining the efficacy of human vaccines that induce antigen-specific protective CD4 T cell responses against pathogens can be particularly challenging to evaluate. Surface expression of CD11a and CD49d has been shown to identify antigen-specific CD4 T cells against viral pathogens in mice. We hypothesized that CD11a and CD49d would also serve as markers of human antigen-specific T cells responding to vaccination.
A phase I vaccine trial enabled us to evaluate a novel gating strategy based on surface expression of CD11a and CD49d as a means of detecting antigen-specific, cytokine producing CD4 and CD8 T cells induced after vaccination of naïve individuals against leishmaniasis. Three study groups received LEISH-F3 recombinant protein combined with either squalene oil-in-water emulsion (SE) alone, SE with the synthetic TLR-4 ligand glucopyranosyl lipid adjuvant (GLA-SE), or SE with Salmonella minnesota-derived monophosphoryl lipid A (MPL-SE). Individuals were given 3 vaccine doses, on days 0, 28 and 168.
Starting after the first vaccine dose, the frequency of both CD11ahiCD49d+ CD4 and CD11ahiCD49d+ CD8 T cells significantly increased over time throughout the 24-week trial. To confirm the role of CD11ahiCD49d+ expression in the identification of the antigen-specific T cells, cytokine production was measured following LEISH-F3 stimulation. All of the IFN-γ, TNF-α, and IL-2 producing cells were found within the CD11ahiCD49d+ population.
Our results suggest that the change in the frequency of CD11ahiCD49d+ T cells can be used to track antigen-specific CD4 and CD8 T cell responses following T cell-targeted vaccination.
Details
- Title: Subtitle
- CD11a and CD49d enhance the detection of antigen-specific T cells following human vaccination
- Creators
- Allison F Christiaansen - Department of Microbiology, University of Iowa, Iowa City, IA 52242, USAUpasna Gaur Dixit - Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USARhea N Coler - Infectious Disease Research Institute, Seattle, WA 98102, USAAnna Marie Beckmann - Infectious Disease Research Institute, Seattle, WA 98102, USASteven G Reed - Infectious Disease Research Institute, Seattle, WA 98102, USAPatricia L Winokur - Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USAM. Bridget Zimmerman - Department of Biostatistics, University of Iowa, Iowa City, IA 52242, USASteven M Varga - Department of Microbiology, University of Iowa, Iowa City, IA 52242, USAMary E Wilson - Department of Microbiology, University of Iowa, Iowa City, IA 52242, USA
- Resource Type
- Journal article
- Publication Details
- Vaccine, Vol.35(33), pp.4255-4261
- DOI
- 10.1016/j.vaccine.2017.06.013
- PMID
- 28662951
- PMCID
- PMC5551405
- NLM abbreviation
- Vaccine
- ISSN
- 0264-410X
- eISSN
- 1873-2518
- Publisher
- Elsevier Ltd
- Grant note
- name: NIH Vaccine Trials and Evaluation Unit, award: HHSN272200800008C; DOI: 10.13039/100000865, name: Bill & Melinda Gates Foundation, award: #39129, OPP1055855
- Language
- English
- Date published
- 07/24/2017
- Academic Unit
- Graduate College Admin and Gen; Microbiology and Immunology; International Programs; Epidemiology; Pathology; Biostatistics; Medicine Administration; Internal Medicine
- Record Identifier
- 9983997365302771
Metrics
27 Record Views